An interventional study of Six-week audio-guided mindfulness program in Type 2 Diabetes Mellitus, Diabetic Autonomic Neuropathy and Anxiety, sponsored by Universitas Sebelas Maret Hospital. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Universitas Sebelas Maret Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 48th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 25 with no phase, and was the 66th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:
Universitas Sriwijaya · Sites in Indonesia
Ages 30–65
Novo Nordisk A/S · Sites in Indonesia, Malaysia, Philippines and 1 more country
Ages 40–70
Indonesia University · Sites in Indonesia
Ages 35–59
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 10 · Phase 4 8
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 85 across the 52 interventional studies, 1,750 across the 14 observational. Of the 47 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 66 have an industry lead sponsor. The 10 most frequent:
Universitas Sebelas Maret Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.
Universitas Sebelas Maret Hospital has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Indonesia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07064486Phase 3BrightGene Bio-Medical Technology Co., Ltd.A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | 2027-04-30 |
| NCT07928661Universitas SriwijayaEffect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | 2026-12 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:
Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.
Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.
This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).
The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.
Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.
The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp.
Behavioral: Six-week audio-guided mindfulness program
Participants continued their standard antidiabetic therapy without the mindfulness program.
A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.
Also known as: Mindfulness-based intervention, MBSR-based audio program
Change in glycated hemoglobin (HbA1c)
HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Change in fasting blood glucose
Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Change in 2-hour postprandial blood glucose
Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Change in standard deviation of normal-to-normal intervals (SDNN)
Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Number of participants with cardiovascular autonomic dysfunction
Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values.
Time frame: Baseline and 6 weeks
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score
HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score
HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value.
Time frame: Baseline and 6 weeks
Plan to share: No — Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Jun 2025, 3 months.
Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 3 months is below that.
Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Sebelas Maret Hospital